India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
The top 15 Indian pharma players have continued to experience anaemic growth in the US market over the five years ended FY22
Amit Jaju, Senior Managing Director, India in an interview with Thomas C Thottathil outlined the steps Indian pharma companies should follow to be compliant with global regulatory requirements
Ex-US revenue rose sharply by 21% YoY to Rs. 22,404 million ($254 million); Operational PAT grew 50.3% YoY to Rs. 5,181 million
In just the last few days, companies including Lupin, Biocon, Alembic Pharmaceuticals and Aurobindo Pharma have announced approvals for 5 mg and 10 mg tablets, all bioequivalent to Farxiga
The goal is to deliver greater value to customers, doctors, and the broader healthcare ecosystem
The US generic market is crucial for Indian pharma, contributing about 35% to its total revenue, around US$ 10.7 billion
Commenced operations in flood-affected Himachal Pradesh
The appointment is effective from May 01, 2023 for five years
Subscribe To Our Newsletter & Stay Updated
